The proprietary technologies include unique degradable amino acid-based poly(ester urea)s and functional poly(propylene fumarate)s. The licensing terms, which were not disclosed, include upfront royalty payments, sponsored research and ongoing royalties. At its onset, the deal represents one of the most significant licensing arrangements by the University in its 148-year history.
Both UA and 21MedTech have ongoing research in the applications of these technologies in drug delivery and resorbable medical devices. The parties recently were awarded a $2 million grant from Ohio Third Frontier for a non-opioid postoperative pain therapy.
“It’s particularly rewarding to see the translation of our fundamental research into therapies and devices designed to help people in such a vast number of indications,” says Becker. “These are disruptive technologies and we are pleased to be working with the medical device and pharmaceutical veterans at 21MedTech.”